Apoptosis

The number of cells in multicellular organism is tightly regulated. Not simply by controlling the rate of cell division, but also by controlling the rate of cell death. If cells are no longer needed, they commit suicide by activating an intracellular death program. This process is therefore called programmed cell death or apoptosis (from a Greek word meaning “falling off,” as leaves from a tree). The intrinsic apoptotic pathway occurs by the release of cytochrome c from mitochondria. The extrinsic apoptotic pathway is caused by the binding of death ligands, such as TNF (tumor necrosis factor), Fas, and TRAIL (TNF-related-apoptosis-inducing ligand), to their corresponding receptors. Although programmed cell death is involved in a number of key biological phenomena, aberrant apoptosis results in diverse human diseases [1]
The amount of apoptosis that occurs in developing and adult animal tissues is surprisingly large. In the developing vertebrate nervous system up to half or more of the nerve cells normally die soon after they are formed. In a healthy adult human, billions of cells die in the bone marrow and intestine every hour. Although this process seems remarkably wasteful -especially as the vast majority are perfectly healthy at the time they kill themselves- programmed cell death plays an important role during embryonic development, as hands and feet, for example, are sculpted by apoptosis: they start out as spadelike structures, and the individual digits separate only as the cells between them die. In other cases, cells die when the structure they form is no longer needed. When a tadpole changes into a frog, the cells in the tail die, and the tail, which is not needed in the frog, disappears. In many other cases, cell death helps regulate cell numbers. In the developing nervous system, for example, cell death adjusts the number of nerve cells to match the number of target cells that require innervation. In all these cases, the cells die by apoptosis as well[2].


[2] D.R. Williams et al. An apoptosis-inducing small molecule that binds to heat shock protein 70. Angew. Chem. Int. Ed. Engl. 2008, 47, 7466-7469.
[1] B. Alberts, A. Johnson, J. Lewis et al. Molecular Biology of the Cell. 4th edition. New York. Garland Science, 2002. 

18 Item(s)

per page
Axon ID Name Description From price
1291 AEG 3482 JNK inhibitor €90.00
2179 ASK1 Inhibitor 10 Potent, selective, and orally bioavailable ASK1 inhibitor €130.00
2002 Bentamapimod JNK inhibitor, which inhibited JNK1, JNK2 and JNK3 €70.00
3697 Binimetinib Potent, selective, non-ATP-competitive and orally available allosteric inhibitor of MEK1/2 €60.00
2025 CC-401 ATP-competitive JNK inhibitor €120.00
2634 CC-930 Potent, selective, and orally active anti-fibrotic JNK inhibitor €95.00
4148 GDC-0973 Orally bioavailable, potent and selective small-molecule inhibitor of mitogen-activated protein kinase 1 Inquire
2949 JNK inhibitor VIII Selective, ATP-competitive, and cell-permeable JNK inhibitor €105.00
2361 JNK-IN-8 Remarkably potent and selective covalent inhibitor of JNK €95.00
3197 Mitochonic acid 5 Mitochondrial drug; Activator of MAPK-ERK-yap signalling €90.00
2366 NG 25 trihydrochloride Type II inhibitor of TAK1 (MAP3K7) and MAP4K2 (GCK) €75.00
1814 NQDI 1 Inhibitor of apoptosis signal-regulating kinase 1 (ASK1) €115.00
1365 PD169316 MAPK inhibitor (p38 specific) €95.00
3874 RDEA119 Potent and highly selective small molecule allosteric MEK inhibitor Inquire
2956 Selonsertib Potent, highly selective, orally available, and ATP-competitive ASK1 inhibitor €90.00
2519 SP 600125 Selective, reversible, and ATP-competitive JNK inhibitor €70.00
2365 SR 3576 Very potent JNK3 inhibitor with >2800-fold selectivity over p38 €135.00
3282 Takinib Potent and selective TAK1 (MAP3K7) inhibitor €105.00

18 Item(s)

per page
Please wait...